Onychomycosis, commonly known as nail fungus, is a fungal infection of the toenails or fingernails. The U.S. market for onychomycosis treatment involves pharmaceutical and healthcare companies that develop and market medications, topical solutions, and other therapeutic interventions.
Kerydin (Tavaborole) Patent Expiry: The key patent for Kerydin, a topical antifungal treatment for onychomycosis, expired in September 2023. This could lead to increased competition and potentially lower prices for patients.
Moberg Pharma Phase 3 Trial: Moberg Pharma, a Danish pharmaceutical company, is conducting a Phase 3 trial for MOB-003, a novel oral therapy for onychomycosis. Positive results could significantly impact the market landscape.
Blueberry Therapeutics Phase 2b Trial: Blueberry Therapeutics is pursuing a Phase 2b trial for its BLU-634 topical gel for onychomycosis. BLU-634 targets a different fungal pathway than existing treatments, offering potential for broader efficacy.
Almirall and Kaken Pharmaceutical Partnership: Almirall, a Spanish pharmaceutical company, entered a partnership with Kaken Pharmaceutical to commercialize Kaken's Luliconazole 5% solution (Luconac R) in the US market. Luconac R is a topical nail lacquer with a unique formulation compared to existing options.
Bausch Health Acquires Valeant Pharmaceuticals: Bausch Health's acquisition of Valeant Pharmaceuticals in May 2023 consolidated its hold on the US onychomycosis market. Valeant previously marketed Jublia (efinaconazole), a topical antifungal treatment.
List of US Onychomycosis Key Companies in the Market
Johnson & Johnson
Novartis AG
Valeant Pharmaceuticals
Pfizer Inc.
Anacor Pharmaceuticals
Galderma S.A.
Moberg Pharma AB
Bayer AG
Dr. Reddy’s Laboratories Ltd.
Cipla Ltd.
Medimetriks Pharmaceuticals Inc
US Onychomycosis Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)